作者: Zachary S. Morris , Jamey P. Weichert , Jarob Saker , Eric A. Armstrong , Abigail Besemer
DOI: 10.1016/J.RADONC.2015.06.015
关键词:
摘要: Abstract Background and purpose CLR1404 is a phospholipid ether that exhibits selective uptake retention in malignant tissues. Radiolabeled enables tumor-specific positron-emission tomography (PET) imaging ( 124 I) targeted delivery of ionizing radiation 131 I). Here we describe the first preclinical studies this diapeutic molecule head neck cancer (HNC) models. Material methods Tumor-selective distribution I-CLR1404 therapeutic efficacy were tested HNC cell lines patient-derived xenograft tumor Monte Carlo dose calculations PET/CT used to examine dosimetry Results including xenografts demonstrate tumor-selective resulting model highly conformal for I-CLR1404. We observe dose-dependent response with respect growth inhibition effect maintained together external beam radiation. Conclusions confirm utility treatment HNC. This promising agent warrants further investigation developing phase I trial combining reduced-dose patients loco-regionally recurrent